2698332316

## RECEIVED 12:49:08 p.m. CENTRAL FAX CENTER

NOV 1 5 2006

PTO/SB/21 (09-04)

11-15-2006

Under the Pagerwork Reduction Act of 1995, no person	U.S. 6	Approved for use through 07/31/2006. CMB 0851-003* Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE lection of information unless it displays a valid OMB control number
	Application Number	10/815589
TRANSMITTAL	Filing Date	April 1, 2004
FORM	First Named Inventor	Adam Rensio
·	Art Unit	1626
(to be used for all correspondence after initial filing)	Examiner Name	Kamal A. Saeed
Total Number of Pages in This Submission 2	Attorney Docket Number	PC27820A
ENCLOSURES (Check all that apply)		
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC
	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Renty	Petition	Appeal Communication to TC
	Petition to Convert to a	(Appeal Notice, Brief, Reply Brief)
	Provisional Application Power of Attorney, Revocation	Proprietary Information
	Change of Correspondence A	ddress Status Letter Other Enclosure(s) (please identify
Extension of Time Request	Terminal Disclatmer	below):
Express Abandonment Request	Request for Refund	
Information Disclosure Statement	CD, Number of CD(s)	
_ [	Landscape Table on CD	<u> </u>
Certified Copy of Priority Remark Document(s)	ks	
Reply to Missing Parts/		
Incomplete Application Reply to Missing Parts		
under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name Pfizer Inc		
Signature   www yary		
Printed name Lucy X, Yang		
Date NOV. 15, 2006	R	eg. No. 40,259
CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature Valletie Solvitale		
Typed or printed name Valerie Schipper	V ()	Date 11-15-2000

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## CENTRAL FAX CENTER

12:49:23 p.m.

11-15-2006

2 /2

NOV 1 5 2006

PATENT/Docket No. PC27820A

Appl. No. 10/815589 Filing Date: 04/01/2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1626

:

**Examiner** 

Kamal A. Saeed

Applicant(s)

Adam Renslo et al.

Serial Number

10/815589

Filed

04/01/2004

For

ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE

Date: NOV. 15,2006

DERIVATIVES AND ANALOGUES

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## RESPONSE TO ELECTION/RESTRICTION

Sir:

Responding to the Election/Restrictions requirement dated October 16, 2006, applicants elect group I drawn to product claims.

Applicants further elect compound 11 at claim 27 (also illustrated in example 11) as a single compound for examination.

Applicants wish to provide a subclass for examination wherein A is structure i; W is -CH<sub>2</sub>-; and Y is  $-SO_{m}$ -, -O-, or  $-N(\mathbb{R}^{8})$ -.

Applicants acknowledge the Examiner's Rejoinder advice wherein; if the product claims are allowable, the method claims commensurate in scope with the product claims will be allowed as well.

If the Examiner believes that personal communications will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this application is respectfully requested.

Respectfully submitted,

Registration No. 40259

Pfizer Inc., Patent Department

7000 Portage Road

Kalamazoo, Michigan 49001

Telephone No. (269) 833-9536 or (269) 833-9500 Telefax No. (269) 833-8897 or (269) 833-2316

> FORM AMEND Rev. 5/27/03